Zimmerman C, Albanese-O'Neill A, Haller MJ. Advances in Type 1 Diabetes Technology Over the Last Decade. Eur Endocrinol. 2019 Aug. 15 (2):70-6. [QxMD MEDLINE Link]. [Full Text].
Bratke H, Margeirsdottir HD, Assmus J, Njolstad PR, Skrivarhaug T. Does Current Diabetes Technology Improve Metabolic Control? A Cross-Sectional Study on the Use of Insulin Pumps and Continuous Glucose Monitoring Devices in a Nationwide Pediatric Population. Diabetes Ther. 2021 Sep. 12 (9):2571-83. [QxMD MEDLINE Link]. [Full Text].
Eiland L, Thangavelu T, Drincic A. Has Technology Improved Diabetes Management in Relation to Age, Gender, and Ethnicity?. Curr Diab Rep. 2019 Nov 4. 19 (11):111. [QxMD MEDLINE Link].
Bailey TS, Walsh J, Stone JY. Emerging Technologies for Diabetes Care. Diabetes Technol Ther. 2018 Jun. 20 (S2):S278-84. [QxMD MEDLINE Link]. [Full Text].
Norgaard K. Telemedicine Consultations and Diabetes Technology During COVID-19. J Diabetes Sci Technol. 2020 Jul. 14 (4):767-8. [QxMD MEDLINE Link]. [Full Text].
Akturk HK, Garg S. Technological advances shaping diabetes care. Curr Opin Endocrinol Diabetes Obes. 2019 Apr. 26 (2):84-9. [QxMD MEDLINE Link].
Phillip M, Bergenstal RM, Close KL, et al. The Digital/Virtual Diabetes Clinic: The Future Is Now-Recommendations from an International Panel on Diabetes Digital Technologies Introduction. Diabetes Technol Ther. 2021 Feb. 23 (2):146-54. [QxMD MEDLINE Link]. [Full Text].
Garg S, Norman GJ. Impact of COVID-19 on Health Economics and Technology of Diabetes Care: Use Cases of Real-Time Continuous Glucose Monitoring to Transform Health Care During a Global Pandemic. Diabetes Technol Ther. 2021 Mar. 23 (S1):S15-S20. [QxMD MEDLINE Link]. [Full Text].
Bornstein SR, Rubino F, Khunti K, et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020 Jun. 8 (6):546-50. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Rodbard D, Hirsch IB, Forlenza GP. Managing New-Onset Type 1 Diabetes During the COVID-19 Pandemic: Challenges and Opportunities. Diabetes Technol Ther. 2020 Jun. 22 (6):431-9. [QxMD MEDLINE Link].
Jones MS, Goley AL, Alexander BE, Keller SB, Caldwell MM, Buse JB. Inpatient Transition to Virtual Care During COVID-19 Pandemic. Diabetes Technol Ther. 2020 Jun. 22 (6):444-8. [QxMD MEDLINE Link]. [Full Text].
Murphy HR. Managing Diabetes in Pregnancy Before, During, and After COVID-19. Diabetes Technol Ther. 2020 Jun. 22 (6):454-61. [QxMD MEDLINE Link]. [Full Text].
Peters AL, Garg SK. The Silver Lining to COVID-19: Avoiding Diabetic Ketoacidosis Admissions with Telehealth. Diabetes Technol Ther. 2020 Jun. 22 (6):449-53. [QxMD MEDLINE Link].
Vigersky RA. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol. 2015 Mar. 9 (2):320-30. [QxMD MEDLINE Link]. [Full Text].
Walker AF, Hood KK, Gurka MJ, et al. Barriers to Technology Use and Endocrinology Care for Underserved Communities With Type 1 Diabetes. Diabetes Care. 2021 Jul. 44 (7):1480-90. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Rewers AH, Akturk HK. Ever-Increasing Insulin-Requiring Patients Globally. Diabetes Technol Ther. 2018 Jun. 20 (S2):S21-4. [QxMD MEDLINE Link]. [Full Text].
Masierek M, Nabrdalik K, Janota O, Kwiendacz H, Macherski M, Gumprecht J. The Review of Insulin Pens-Past, Present, and Look to the Future. Front Endocrinol (Lausanne). 2022. 13:827484. [QxMD MEDLINE Link]. [Full Text].
van den Boom L, Karges B, Auzanneau M, et al. Temporal Trends and Contemporary Use of Insulin Pump Therapy and Glucose Monitoring Among Children, Adolescents, and Adults With Type 1 Diabetes Between 1995 and 2017. Diabetes Care. 2019 Nov. 42 (11):2050-6. [QxMD MEDLINE Link]. [Full Text].
Gajewska KA, Biesma R, Bennett K, Sreenan S. Barriers and facilitators to accessing insulin pump therapy by adults with type 1 diabetes mellitus: a qualitative study. Acta Diabetol. 2021 Jan. 58 (1):93-105. [QxMD MEDLINE Link].
International Diabetes Federation. IDF Diabetes Atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2022. [Full Text].
US Centers for Disease Control and Prevention. National Diabetes Statistics Report 2020: Estimates of Diabetes and Its Burden in the United States. CDC. Available at https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed: July 5, 2022.
Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009 Summer. 19 (3):288-92. [QxMD MEDLINE Link]. [Full Text].
Beckles GL, Chou CF. Disparities in the Prevalence of Diagnosed Diabetes - United States, 1999-2002 and 2011-2014. MMWR Morb Mortal Wkly Rep. 2016 Nov 18. 65 (45):1265-9. [QxMD MEDLINE Link]. [Full Text].
Wilf-Miron R, Peled R, Yaari E, et al. Disparities in diabetes care: role of the patient's socio-demographic characteristics. BMC Public Health. 2010 Nov 25. 10:729. [QxMD MEDLINE Link]. [Full Text].
Lado JJ, Lipman TH. Racial and Ethnic Disparities in the Incidence, Treatment, and Outcomes of Youth with Type 1 Diabetes. Endocrinol Metab Clin North Am. 2016 Jun. 45 (2):453-61. [QxMD MEDLINE Link].
Addala A, Auzanneau M, Miller K, et al. A Decade of Disparities in Diabetes Technology Use and HbA1c in Pediatric Type 1 Diabetes: A Transatlantic Comparison. Diabetes Care. 2021 Jan. 44 (1):133-40. [QxMD MEDLINE Link]. [Full Text].
Agarwal S, Schechter C, Gonzalez J, Long JA. Racial-Ethnic Disparities in Diabetes Technology use Among Young Adults with Type 1 Diabetes. Diabetes Technol Ther. 2021 Apr. 23 (4):306-13. [QxMD MEDLINE Link]. [Full Text].
McKergow E, Parkin L, Barson DJ, Sharples KJ, Wheeler BJ. Demographic and regional disparities in insulin pump utilization in a setting of universal funding: a New Zealand nationwide study. Acta Diabetol. 2017 Jan. 54 (1):63-71. [QxMD MEDLINE Link].
Agarwal S, Simmonds I, Myers AK. The Use of Diabetes Technology to Address Inequity in Health Outcomes: Limitations and Opportunities. Curr Diab Rep. 2022 Jul. 22 (7):275-281. [QxMD MEDLINE Link]. [Full Text].
American Diabetes Association. Economic Costs of Diabetes in the U.S. in 2017. Diabetes Care. 2018 May. 41 (5):917-28. [QxMD MEDLINE Link]. [Full Text].
Deeb LC. Diabetes Technology During the Past 30 Years: A Lot of Changes and Mostly for the Bette. Diabetes Spectrum. 2008. 21 (2):[Full Text].
Distiller LA. Why do some patients with type 1 diabetes live so long?. World J Diabetes. 2014 Jun 15. 5 (3):282-7. [QxMD MEDLINE Link]. [Full Text].
Sussman M, Benner J, Haller MJ, Rewers M, Griffiths R. Estimated Lifetime Economic Burden of Type 1 Diabetes. Diabetes Technol Ther. 2020 Feb. 22 (2):121-30. [QxMD MEDLINE Link]. [Full Text].
Rawshani A, Rawshani A, Franzen S, et al. Mortality and Cardiovascular Disease in Type 1 and Type 2 Diabetes. N Engl J Med. 2017 Apr 13. 376 (15):1407-18. [QxMD MEDLINE Link]. [Full Text].
Huo L, Harding JL, Peeters A, Shaw JE, Magliano DJ. Life expectancy of type 1 diabetic patients during 1997-2010: a national Australian registry-based cohort study. Diabetologia. 2016 Jun. 59 (6):1177-85. [QxMD MEDLINE Link]. [Full Text].
Heald AH, Stedman M, Davies M, et al. Estimating life years lost to diabetes: outcomes from analysis of National Diabetes Audit and Office of National Statistics data. Cardiovasc Endocrinol Metab. 2020 Dec. 9 (4):183-5. [QxMD MEDLINE Link]. [Full Text].
Tran-Duy A, Knight J, Clarke PM, Svensson AM, Eliasson B, Palmer AJ. Development of a life expectancy table for individuals with type 1 diabetes. Diabetologia. 2021 Oct. 64 (10):2228-36. [QxMD MEDLINE Link]. [Full Text].
Hirsch IB. Introduction: History of Glucose Monitoring. Hirsch IB, Battelino T, Peters AL, Chamberlain JJ, Aleppo G, Bergenstal RM. Role of Continuous Glucose Monitoring in Diabetes Treatment. Arlington, Va: American Diabetes Association; 2018. [Full Text].
Schnell O, Barnard K, Bergenstal R, et al. Clinical Utility of SMBG: Recommendations on the Use and Reporting of SMBG in Clinical Research. Diabetes Care. 2015 Sep. 38 (9):1627-33. [QxMD MEDLINE Link]. [Full Text].
Sherwood JS, Russell SJ, Putman MS. New and Emerging Technologies in Type 1 Diabetes. Endocrinol Metab Clin North Am. 2020 Dec. 49 (4):667-78. [QxMD MEDLINE Link]. [Full Text].
Rodbard D. Continuous Glucose Monitoring: A Review of Recent Studies Demonstrating Improved Glycemic Outcomes. Diabetes Technol Ther. 2017 Jun. 19 (S3):S25-S37. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Liljenquist D, Bode B, et al. Evaluation of Accuracy and Safety of the Next-Generation Up to 180-Day Long-Term Implantable Eversense Continuous Glucose Monitoring System: The PROMISE Study. Diabetes Technol Ther. 2022 Feb. 24 (2):84-92. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Potts RO, Ackerman NR, Fermi SJ, Tamada JA, Chase HP. Correlation of fingerstick blood glucose measurements with GlucoWatch biographer glucose results in young subjects with type 1 diabetes. Diabetes Care. 1999 Oct. 22 (10):1708-14. [QxMD MEDLINE Link]. [Full Text].
Tamada JA, Garg S, Jovanovic L, Pitzer KR, Fermi S, Potts RO. Noninvasive glucose monitoring: comprehensive clinical results. Cygnus Research Team. JAMA. 1999 Nov 17. 282 (19):1839-44. [QxMD MEDLINE Link]. [Full Text].
Chase HP, Roberts MD, Wightman C, et al. Use of the GlucoWatch biographer in children with type 1 diabetes. Pediatrics. 2003 Apr. 111 (4 Pt 1):790-4. [QxMD MEDLINE Link].
Garg SK, Schwartz S, Edelman SV. Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetes. Diabetes Care. 2004 Mar. 27 (3):734-8. [QxMD MEDLINE Link]. [Full Text].
Garg S, Zisser H, Schwartz S, et al. Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trial. Diabetes Care. 2006 Jan. 29 (1):44-50. [QxMD MEDLINE Link]. [Full Text].
Garg S, Jovanovic L. Relationship of fasting and hourly blood glucose levels to HbA1c values: safety, accuracy, and improvements in glucose profiles obtained using a 7-day continuous glucose sensor. Diabetes Care. 2006 Dec. 29 (12):2644-9. [QxMD MEDLINE Link]. [Full Text].
Ellis SL, Bookout T, Garg SK, Izuora KE. Use of continuous glucose monitoring to improve diabetes mellitus management. Endocrinol Metab Clin North Am. 2007 Dec. 36 Suppl 2:46-68. [QxMD MEDLINE Link].
Garg SK, Voelmle MK, Gottlieb P. Feasibility of 10-day use of a continuous glucose-monitoring system in adults with type 1 diabetes. Diabetes Care. 2009 Mar. 32 (3):436-8. [QxMD MEDLINE Link]. [Full Text].
Blevins TC, Bode BW, Garg SK, et al. Statement by the American Association of Clinical Endocrinologists Consensus Panel on continuous glucose monitoring. Endocr Pract. 2010 Sep-Oct. 16 (5):730-45. [QxMD MEDLINE Link].
Garg SK, Voelmle MK, Beatson CR, et al. Use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injections versus continuous subcutaneous insulin infusion therapy: a prospective 6-month study. Diabetes Care. 2011 Mar. 34 (3):574-9. [QxMD MEDLINE Link]. [Full Text].
Moser EG, Morris AA, Garg SK. Emerging diabetes therapies and technologies. Diabetes Res Clin Pract. 2012 Jul. 97 (1):16-26. [QxMD MEDLINE Link]. [Full Text].
Garg SK. Glucose monitoring: an important tool for improving glucose control and reducing hypoglycemia. Diabetes Technol Ther. 2008 Jun. 10 (Suppl 1):S1-4.
Garg SK. The future of continuous glucose monitoring. Diabetes Technol Ther. 2009 Jun. 11 Suppl 1:S1-3. [QxMD MEDLINE Link].
Rodbard D, Bailey T, Jovanovic L, Zisser H, Kaplan R, Garg SK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther. 2009 Nov. 11 (11):717-23. [QxMD MEDLINE Link]. [Full Text].
Reddy N, Verma N, Dungan K, et al. Monitoring Technologies- Continuous Glucose Monitoring, Mobile Technology, Biomarkers of Glycemic Control. Endotext. 2020 Aug 16. [QxMD MEDLINE Link]. [Full Text].
Facchinetti A. Continuous Glucose Monitoring Sensors: Past, Present and Future Algorithmic Challenges. Sensors (Basel). 2016 Dec 9. 16 (12):[QxMD MEDLINE Link]. [Full Text].
Smith MB, Albanese-O'Neill A, Macieira TGR, et al. Human Factors Associated with Continuous Glucose Monitor Use in Patients with Diabetes: A Systematic Review. Diabetes Technol Ther. 2019 Oct. 21 (10):589-601. [QxMD MEDLINE Link].
Tucker ME. 'Smart' Insulin Pen With CGM First to Launch in Emerging Field. Medscape Medical News. 2020 Nov 17. [Full Text].
Close KL. CGM Users Worldwide. Close Concerns. 2022.
Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomized Clinical Trial. JAMA. 2017 Jan 24. 317 (4):379-87. [QxMD MEDLINE Link]. [Full Text].
Beck RW, Riddlesworth TD, Ruedy K, et al. Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. Ann Intern Med. 2017 Sep 19. 167 (6):365-74. [QxMD MEDLINE Link].
Martens T, Beck RW, Bailey R, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin: A Randomized Clinical Trial. JAMA. 2021 Jun 8. 325 (22):2262-72. [QxMD MEDLINE Link]. [Full Text].
Soliman A, DeSanctis V, Yassin M, Elalaily R, Eldarsy NE. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab. 2014 May. 18 (3):274-82. [QxMD MEDLINE Link]. [Full Text].
Steck AK, Dong F, Geno Rasmussen C, et al. CGM Metrics Predict Imminent Progression to Type 1 Diabetes: Autoimmunity Screening for Kids (ASK) Study. Diabetes Care. 2022 Feb 1. 45 (2):365-71. [QxMD MEDLINE Link].
Steck AK, Dong F, Taki I, et al. Continuous Glucose Monitoring Predicts Progression to Diabetes in Autoantibody Positive Children. J Clin Endocrinol Metab. 2019 Aug 1. 104 (8):3337-44. [QxMD MEDLINE Link]. [Full Text].
Charleer S, Mathieu C, Nobels F, et al. Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study. J Clin Endocrinol Metab. 2018 Mar 1. 103 (3):1224-32. [QxMD MEDLINE Link]. [Full Text].
Gross TM, Bode BW, Einhorn D, et al. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000 Spring. 2 (1):49-56. [QxMD MEDLINE Link].
Tierney MJ, Tamada JA, Potts RO, Jovanovic L, Garg S, Cygnus Research Team. Clinical evaluation of the GlucoWatch biographer: a continual, non-invasive glucose monitor for patients with diabetes. Biosens Bioelectron. 2001 Dec. 16 (9-12):621-9. [QxMD MEDLINE Link].
Zisser HC, Bailey TS, Schwartz S, Ratner RE, Wise J. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. J Diabetes Sci Technol. 2009 Sep 1. 3 (5):1146-54. [QxMD MEDLINE Link]. [Full Text].
Didyuk O, Econom N, Guardia A, Livingston K, Klueh U. Continuous Glucose Monitoring Devices: Past, Present, and Future Focus on the History and Evolution of Technological Innovation. J Diabetes Sci Technol. 2021 May. 15 (3):676-83. [QxMD MEDLINE Link]. [Full Text].
Boscari F, Vettoretti M, Cavallin F, et al. Implantable and transcutaneous continuous glucose monitoring system: a randomized cross over trial comparing accuracy, efficacy and acceptance. J Endocrinol Invest. 2022 Jan. 45 (1):115-24. [QxMD MEDLINE Link]. [Full Text].
Coverage and Coding of Continuous Glucose Monitors. Medical Minute MD. Available at https://www.cgsmedicare.com/jc/education/video/mm/GSM.pdf. March 15, 2017; Accessed: August 3, 2022.
FDA authorizes first fully interoperable continuous glucose monitoring system, streamlines review pathway for similar devices. US Food and Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review. March 27, 2018; Accessed: June 6, 2022.
Tucker ME. FDA Okays New Interoperable Continuous Glucose Monitor. Medscape Medical News. 2018 Mar 27. [Full Text].
De Novo request for classification of the Dexcom G6 Continuous Glucose Monitoring System: Results. FDA. Available at https://www.accessdata.fda.gov/cdrh_docs/pdf17/DEN170088.pdf. March 27, 2018; Accessed: July 6, 2022.
Teymourian H, Moonla C, Tehrani F, et al. Microneedle-Based Detection of Ketone Bodies along with Glucose and Lactate: Toward Real-Time Continuous Interstitial Fluid Monitoring of Diabetic Ketosis and Ketoacidosis. Anal Chem. 2020 Jan 21. 92 (2):2291-300. [QxMD MEDLINE Link].
Blum A. Freestyle Libre Glucose Monitoring System. Clin Diabetes. 2018 Apr. 36 (2):203-4. [QxMD MEDLINE Link]. [Full Text].
Crabtree TSJ, Choudhary P, Kar P, Wilmot EG. Flash glucose monitoring: the story so far and the journey ahead. BMJ Innovations. 2022 Apr 25. [Full Text].
Flash Glucose Monitors (FreeStyle Libre) and Continuous Glucose Monitors (CGM). Diabetes UK. Available at https://www.diabetes.org.uk/guide-to-diabetes/diabetes-technology/flash-glucose-monitors-and-continuous-glucose-monitors. Accessed: August 19, 2022.
Wysham CH, Kruger DF. Practical Considerations for Initiating and Utilizing Flash Continuous Glucose Monitoring in Clinical Practice. J Endocr Soc. 2021 Sep 1. 5 (9):bvab064. [QxMD MEDLINE Link]. [Full Text].
Alva S, Bailey T, Brazg R, et al. Accuracy of a 14-Day Factory-Calibrated Continuous Glucose Monitoring System With Advanced Algorithm in Pediatric and Adult Population With Diabetes. J Diabetes Sci Technol. 2022 Jan. 16 (1):70-7. [QxMD MEDLINE Link]. [Full Text].
Whooley S. FDA clears Abbott’s next-gen FreeStyle Libre 3 14-day CGM. Drug Delivery Business News. Available at https://www.drugdeliverybusiness.com/fda-abbott-next-gen-freestyle-libre-3-cgm/. May 31, 2022; Accessed: July 6, 2022.
Tweden KS, Deiss D, Rastogi R, Addaguduru S, Kaufman FR. Longitudinal Analysis of Real-World Performance of an Implantable Continuous Glucose Sensor over Multiple Sensor Insertion and Removal Cycles. Diabetes Technol Ther. 2020 May. 22 (5):422-7. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. FDA Approves First Implantable Continuous Glucose Monitor. Medscape Medical News. 2018 Jun 21. [Full Text].
Eversense E3 Continuous Glucose Monitoring System - P160048/S016. US Food and Drug Administration. Available at https://www.fda.gov/medical-devices/eversense-e3-continuous-glucose-monitoring-system-p160048s016. Accessed: August 18, 2022.
Kompala T, Neinstein A. A new era: increasing continuous glucose monitoring use in type 2 diabetes. Am J Manag Care. 2019 Mar. 25 (4 Spec No.):SP123-6. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. Noninvasive, Low Cost CGM for Type 2 Diabetes Coming in US and EU. Medscape Medical News. 2020 Dec 2. [Full Text].
Hartman I. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence. Clin Med Res. 2008 Sep. 6 (2):54-67. [QxMD MEDLINE Link]. [Full Text].
Diabetes Control and Complications Trial Research Group, Nathan DM, Genuth S, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 Sep 30. 329 (14):977-86. [QxMD MEDLINE Link]. [Full Text].
Berget C, Messer LH, Forlenza GP. A Clinical Overview of Insulin Pump Therapy for the Management of Diabetes: Past, Present, and Future of Intensive Therapy. Diabetes Spectr. 2019 Aug. 32 (3):194-204. [QxMD MEDLINE Link]. [Full Text].
Aleppo G. Insulin Pump Overview. Endocrineweb. Available at https://www.endocrineweb.com/guides/insulin/insulin-pump-overview. Updated March 5, 2019; Accessed: August 23, 2022.
Alsaleh FM, Smith FJ, Keady S, Taylor KM. Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther. 2010 Apr. 35 (2):127-38. [QxMD MEDLINE Link]. [Full Text].
Fogt EJ, Dodd LM, Jenning EM, Clemens AH. Development and evaluation of a glucose analyzer for a glucose controlled insulin infusion system ((Biostator). Clin Chem. 1978 Aug. 24 (8):1366-72. [QxMD MEDLINE Link].
Alsaleh FM, Smith FJ, Keady S, Taylor KM. Insulin pumps: from inception to the present and toward the future. J Clin Pharm Ther. 2010 Apr. 35 (2):127-38. [QxMD MEDLINE Link]. [Full Text].
Kesavadev J, Saboo B, Krishna MB, Krishnan G. Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas. Diabetes Ther. 2020 Jun. 11 (6):1251-69. [QxMD MEDLINE Link]. [Full Text].
Weaver KW, Hirsch IB. The Hybrid Closed-Loop System: Evolution and Practical Applications. Diabetes Technol Ther. 2018 Jun. 20 (S2):S216-23. [QxMD MEDLINE Link]. [Full Text].
Allen N, Gupta A. Current Diabetes Technology: Striving for the Artificial Pancreas. Diagnostics (Basel). 2019 Mar 15. 9 (1):[QxMD MEDLINE Link]. [Full Text].
Zisser HC. The OmniPod Insulin Management System: the latest innovation in insulin pump therapy. Diabetes Ther. 2010 Aug. 1 (1):10-24. [QxMD MEDLINE Link]. [Full Text].
Schaeffer NE. Human factors research applied: the development of a personal touch screen insulin pump and users' perceptions of actual use. Diabetes Technol Ther. 2013 Oct. 15 (10):845-54. [QxMD MEDLINE Link].
FDA approves first automated insulin delivery device for type 1 diabetes. US Food and Drug Administration. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm522974.htm. September 28, 2016; Accessed: August 19, 2022.
Mastrototaro J, Shin J, Marcus A, Sulur G, STAR 1 Clinical Trial Investigators. The accuracy and efficacy of real-time continuous glucose monitoring sensor in patients with type 1 diabetes. Diabetes Technol Ther. 2008 Oct. 10 (5):385-90. [QxMD MEDLINE Link].
Agrawal P, Welsh JB, Kannard B, Askari S, Yang Q, Kaufman FR. Usage and effectiveness of the low glucose suspend feature of the Medtronic Paradigm Veo insulin pump. J Diabetes Sci Technol. 2011 Sep 1. 5 (5):1137-41. [QxMD MEDLINE Link]. [Full Text].
Garg S, Brazg RL, Bailey TS, et al. Reduction in duration of hypoglycemia by automatic suspension of insulin delivery: the in-clinic ASPIRE study. Diabetes Technol Ther. 2012 Mar. 14 (3):205-9. [QxMD MEDLINE Link].
Bergenstal RM, Klonoff DC, Garg SK, et al. Threshold-based insulin-pump interruption for reduction of hypoglycemia. N Engl J Med. 2013 Jul 18. 369 (3):224-32. [QxMD MEDLINE Link]. [Full Text].
Zhong A, Choudhary P, McMahon C, et al. Effectiveness of Automated Insulin Management Features of the MiniMed® 640G Sensor-Augmented Insulin Pump. Diabetes Technol Ther. 2016 Oct. 18 (10):657-63. [QxMD MEDLINE Link]. [Full Text].
Buckingham BA, Bailey TS, Christiansen M, et al. Evaluation of a Predictive Low-Glucose Management System In-Clinic. Diabetes Technol Ther. 2017 May. 19 (5):288-92. [QxMD MEDLINE Link].
Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 Diabetes. JAMA. 2016 Oct 4. 316 (13):1407-8. [QxMD MEDLINE Link].
Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose Outcomes with the In-Home Use of a Hybrid Closed-Loop Insulin Delivery System in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2017 Mar. 19 (3):155-63. [QxMD MEDLINE Link]. [Full Text].
FDA Approves Hybrid Closed Loop System for People with Type 1 Diabetes. Endocrine News. Available at https://endocrinenews.endocrine.org/medtronic-receives-fda-approval-for-hybrid-closed-loop-system-for-people-with-type-1-diabetes/. September 2016; Accessed: August 5, 2022.
Messer LH, Berget C, Forlenza GP. A Clinical Guide to Advanced Diabetes Devices and Closed-Loop Systems Using the CARES Paradigm. Diabetes Technol Ther. 2019 Aug. 21 (8):462-9. [QxMD MEDLINE Link]. [Full Text].
Boughton CK, Hovorka R. New closed-loop insulin systems. Diabetologia. 2021 May. 64 (5):1007-15. [QxMD MEDLINE Link]. [Full Text].
Forlenza GP, Pinhas-Hamiel O, Liljenquist DR, et al. Safety Evaluation of the MiniMed 670G System in Children 7-13 Years of Age with Type 1 Diabetes. Diabetes Technol Ther. 2019 Jan. 21 (1):11-9. [QxMD MEDLINE Link]. [Full Text].
Knebel T, Neumiller JJ. Medtronic MiniMed 670G Hybrid Closed-Loop System. Clin Diabetes. 2019 Jan. 37 (1):94-5. [QxMD MEDLINE Link]. [Full Text].
Nimri R, Grosman B, Roy A, et al. Feasibility Study of a Hybrid Closed-Loop System with Automated Insulin Correction Boluses. Diabetes Technol Ther. 2021 Apr. 23 (4):268-76. [QxMD MEDLINE Link].
Carlson AL, Sherr JL, Shulman DI, et al. Safety and Glycemic Outcomes During the MiniMed™ Advanced Hybrid Closed-Loop System Pivotal Trial in Adolescents and Adults with Type 1 Diabetes. Diabetes Technol Ther. 2022 Mar. 24 (3):178-89. [QxMD MEDLINE Link]. [Full Text].
FDA Roundup: April 21, 2023. US Food & Drug Administration. Available at https://www.fda.gov/news-events/press-announcements/fda-roundup-april-21-2023. April 21, 2023; Accessed: April 27, 2023.
Peters AL. Why the Approval of MiniMed 780G Is a 'Quantum Leap' Forward. Medscape Diabetes & Endocrinology. Available at https://www.medscape.com/viewarticle/991154?src=. April 26, 2023; Accessed: April 27, 2023.
McCall B. UK Launch for Most Advanced 'Artificial Pancreas', MiniMed 780G. Medscape Medical News. 2021 Jan 27. [Full Text].
Bergenstal RM, Nimri R, Beck RW, et al. A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet. 2021 Jan 16. 397 (10270):208-19. [QxMD MEDLINE Link]. [Full Text].
Silva JD, Lepore G, Battelino T, et al. Real-World Performance of the MiniMed™ 780G System: First Report of Outcomes from 4120 Users. Diabetes Technol Ther. 2022 Feb. 24 (2):113-9. [QxMD MEDLINE Link]. [Full Text].
Collyns OJ, Meier RA, Betts ZL, et al. Improved Glycemic Outcomes With Medtronic MiniMed Advanced Hybrid Closed-Loop Delivery: Results From a Randomized Crossover Trial Comparing Automated Insulin Delivery With Predictive Low Glucose Suspend in People With Type 1 Diabetes. Diabetes Care. 2021 Apr. 44 (4):969-75. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. FDA Approves First Interoperable Insulin Pump. Medscape Medical News. 2019 Feb 19. [Full Text].
Messer LH, Campbell K, Pyle L, Forlenza GP. Basal-IQ technology in the real world: satisfaction and reduction of diabetes burden in individuals with type 1 diabetes. Diabet Med. 2021 Jun. 38 (6):e14381. [QxMD MEDLINE Link].
Pinsker JE, Muller L, Constantin A, et al. Real-World Patient-Reported Outcomes and Glycemic Results with Initiation of Control-IQ Technology. Diabetes Technol Ther. 2021 Feb. 23 (2):120-7. [QxMD MEDLINE Link]. [Full Text].
Forlenza GP, Li Z, Buckingham BA, et al. Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial. Diabetes Care. 2018 Oct. 41 (10):2155-61. [QxMD MEDLINE Link]. [Full Text].
Breton MD, Kovatchev BP. One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology. Diabetes Technol Ther. 2021 Sep. 23 (9):601-8. [QxMD MEDLINE Link]. [Full Text].
Brown SA, Forlenza GP, Bode BW, et al. Multicenter Trial of a Tubeless, On-Body Automated Insulin Delivery System With Customizable Glycemic Targets in Pediatric and Adult Participants With Type 1 Diabetes. Diabetes Care. 2021 Jul. 44 (7):1630-40. [QxMD MEDLINE Link]. [Full Text].
Buckingham BA, Forlenza GP, Pinsker JE, et al. Safety and Feasibility of the OmniPod Hybrid Closed-Loop System in Adult, Adolescent, and Pediatric Patients with Type 1 Diabetes Using a Personalized Model Predictive Control Algorithm. Diabetes Technol Ther. 2018 Apr. 20 (4):257-62. [QxMD MEDLINE Link]. [Full Text].
Sherr JL, Bode BW, Forlenza GP, et al. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single-Arm Multicenter Clinical Trial. Diabetes Care. 2022 Aug 1. 45 (8):1907-10. [QxMD MEDLINE Link]. [Full Text].
Tucker ME. FDA Okays First Tubing-Free 'Artificial Pancreas' Omnipod 5. Medscape Medical News. 2022 Jan 28. [Full Text].
Petrovski G, Al Khalaf F, Campbell J, et al. One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes. Acta Diabetol. 2021 Feb. 58 (2):207-13. [QxMD MEDLINE Link]. [Full Text].
Tornese G, Buzzurro F, Carletti C, Faleschini E, Barbi E. Six-Month Effectiveness of Advanced vs. Standard Hybrid Closed-Loop System in Children and Adolescents With Type 1 Diabetes Mellitus. Front Endocrinol (Lausanne). 2021. 12:766314. [QxMD MEDLINE Link]. [Full Text].
Janez A, Battelino T, Klupa T, et al. Hybrid Closed-Loop Systems for the Treatment of Type 1 Diabetes: A Collaborative, Expert Group Position Statement for Clinical Use in Central and Eastern Europe. Diabetes Ther. 2021 Dec. 12 (12):3107-35. [QxMD MEDLINE Link]. [Full Text].
Brown SA, Kovatchev BP, Raghinaru D, et al. Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. N Engl J Med. 2019 Oct 31. 381 (18):1707-17. [QxMD MEDLINE Link]. [Full Text].
Moreno-Fernandez J, García-Seco JA. Commercialized Hybrid Closed-Loop System (Minimed Medtronic 670G) Results During Pregnancy. AACE Clin Case Rep. 2021 May-Jun. 7 (3):177-9. [QxMD MEDLINE Link]. [Full Text].
Feig DS, Donovan LE, Corcoy R, et al. Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial. Lancet. 2017 Nov 25. 390 (10110):2347-59. [QxMD MEDLINE Link]. [Full Text].
Feig DS, Corcoy R, Donovan LE, et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care. 2018 Dec. 41 (12):2471-9. [QxMD MEDLINE Link]. [Full Text].
Wilson LM, Jacobs PG, Ramsey KL, et al. Dual-Hormone Closed-Loop System Using a Liquid Stable Glucagon Formulation Versus Insulin-Only Closed-Loop System Compared With a Predictive Low Glucose Suspend System: An Open-Label, Outpatient, Single-Center, Crossover, Randomized Controlled Trial. Diabetes Care. 2020 Nov. 43 (11):2721-9. [QxMD MEDLINE Link]. [Full Text].
Tsoukas MA, Cohen E, Legault L, et al. Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies. Diabetes Obes Metab. 2021 Sep. 23 (9):2090-8. [QxMD MEDLINE Link].
Weinzimer SA, Sherr JL, Cengiz E, et al. Effect of pramlintide on prandial glycemic excursions during closed-loop control in adolescents and young adults with type 1 diabetes. Diabetes Care. 2012 Oct. 35 (10):1994-9. [QxMD MEDLINE Link]. [Full Text].
Wilson LM, Jacobs PG, Castle JR. Role of Glucagon in Automated Insulin Delivery. Endocrinol Metab Clin North Am. 2020 Mar. 49 (1):179-202. [QxMD MEDLINE Link]. [Full Text].
El-Khatib FH, Balliro C, Hillard MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet. 2017 Jan 28. 389 (10067):369-80. [QxMD MEDLINE Link]. [Full Text].
Haidar A, Tsoukas MA, Bernier-Twardy S, et al. A Novel Dual-Hormone Insulin-and-Pramlintide Artificial Pancreas for Type 1 Diabetes: A Randomized Controlled Crossover Trial. Diabetes Care. 2020 Mar. 43 (3):597-606. [QxMD MEDLINE Link]. [Full Text].
Daly AB, Boughton CK, Nwokolo M, et al. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nat Med. 2023 Jan 11. [QxMD MEDLINE Link]. [Full Text].
[Guideline] University of Cambridge. Artificial Pancreas Developed That Can Help Maintain Healthy Glucose Levels in Type 2 Diabetes Patients. SciTechDaily. Available at https://scitechdaily.com/artificial-pancreas-developed-that-can-help-maintain-healthy-glucose-levels-in-type-2-diabetes-patients/. January 11, 2023; Accessed: January 13, 2023.
Randelovic S, Bipat R. A Review of Coumarins and Coumarin-Related Compounds for Their Potential Antidiabetic Effect. Clin Med Insights Endocrinol Diabetes. 2021. 14:11795514211042023. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Hoff HK, Chase HP. The role of continuous glucose sensors in diabetes care. Endocrinol Metab Clin North Am. 2004 Mar. 33 (1):163-73, x-xi. [QxMD MEDLINE Link].
Lal RA, Basina M, Maahs DM, Hood K, Buckingham B, Wilson DM. One Year Clinical Experience of the First Commercial Hybrid Closed-Loop System. Diabetes Care. 2019 Dec. 42 (12):2190-6. [QxMD MEDLINE Link]. [Full Text].
Christiansen MP, Garg SK, Brazg R, et al. Accuracy of a Fourth-Generation Subcutaneous Continuous Glucose Sensor. Diabetes Technol Ther. 2017 Aug. 19 (8):446-56. [QxMD MEDLINE Link]. [Full Text].
Whooley S. Medtronic wins CE mark for smart insulin pen, Guardian 4 sensor. Drug Delivery Business News. Available at https://www.drugdeliverybusiness.com/medtronic-wins-ce-mark-for-smart-insulin-pen-cgm-system/. May 26, 2021; Accessed: July 6, 2022.
Whooley S. Medtronic CEO confirms FDA warning could affect approval timing for next-gen diabetes tech. Drug Delivery Business News. Available at https://www.drugdeliverybusiness.com/medtronic-ceo-confirms-fda-warning-affects-approval-timing-for-next-gen-diabetes-tech-updates-on-pipeline/. January 10, 2022; Accessed: July 6, 2022.
Nakamura K, Balo A. The Accuracy and Efficacy of the Dexcom G4 Platinum Continuous Glucose Monitoring System. J Diabetes Sci Technol. 2015 Mar 23. 9 (5):1021-6. [QxMD MEDLINE Link]. [Full Text].
Link M, Kamecke U, Waldenmaier D, Pleus S, Garcia A, Haug C, et al. Comparative Accuracy Analysis of a Real-time and an Intermittent-Scanning Continuous Glucose Monitoring System. J Diabetes Sci Technol. 2021 Mar. 15 (2):287-93. [QxMD MEDLINE Link]. [Full Text].
Garg SK, Kipnes M, Castorino K, et al. Accuracy and Safety of Dexcom G7 Continuous Glucose Monitoring in Adults with Diabetes. Diabetes Technol Ther. 2022 Jun. 24 (6):373-80. [QxMD MEDLINE Link]. [Full Text].
Weinstein RL, Schwartz SL, Brazg RL, Bugler JR, Peyser TA, McGarraugh GV. Accuracy of the 5-day FreeStyle Navigator Continuous Glucose Monitoring System: comparison with frequent laboratory reference measurements. Diabetes Care. 2007 May. 30 (5):1125-30. [QxMD MEDLINE Link]. [Full Text].
Rao H, Fakourfar N, Sun C, Lewis J. The Use of Continuous Glucose Monitoring in Older People With Type 2 Diabetes. Sr Care Pharm. 2021 Nov 1. 36 (11):556-67. [QxMD MEDLINE Link].
Burckhardt MA, Fried L, Bebbington K, et al. Use of remote monitoring with continuous glucose monitoring in young children with Type 1 diabetes: the parents' perspective. Diabet Med. 2019 Nov. 36 (11):1453-9. [QxMD MEDLINE Link].
Agarwal S, Mathew J, Davis GM, et al. Continuous Glucose Monitoring in the Intensive Care Unit During the COVID-19 Pandemic. Diabetes Care. 2021 Mar. 44 (3):847-9. [QxMD MEDLINE Link]. [Full Text].
Andres E, Meyer L, Zulfiqar AA, et al. Telemonitoring in diabetes: evolution of concepts and technologies, with a focus on results of the more recent studies. J Med Life. 2019 Jul-Sep. 12 (3):203-14. [QxMD MEDLINE Link]. [Full Text].
Dairman T. Deltec Cozmo Pump Discontinued. Diabetes Self-Management. Available at https://www.diabetesselfmanagement.com/blog/deltec-cozmo-pump-discontinued/. April 10, 2009; Accessed: July 7, 2022.
Animas Corporation to Close Operations and Exit Insulin Pump Market. Johnson & Johnson. Available at https://www.jnj.com/media-center/press-releases/animas-corporation-to-close-operations-and-exit-insulin-pump-market. October 5, 2017; Accessed: July 7, 2022.
Hoskins M. Roche Hands Over Remaining U.S. Insulin Pump Customers to Medtronic. Healthline. Available at https://www.healthline.com/diabetesmine/roche-hands-off-remaining-pump-customers-medtronic#1. June 1, 2018; Accessed: July 7, 2022.
Kaleido. Available at https://www.hellokaleido.com/. Accessed: July 7, 2022.
SOOIL Development Co. Available at https://sooil.com/about/history.php. Accessed: July 7, 2022.
Zhou K, Isaacs D. Closed-Loop Artificial Pancreas Therapy for Type 1 Diabetes. Curr Cardiol Rep. 2022 Jun 21. [QxMD MEDLINE Link].
Amadou C, Franc S, Benhamou PY, et al. Diabeloop DBLG1 Closed-Loop System Enables Patients With Type 1 Diabetes to Significantly Improve Their Glycemic Control in Real-Life Situations Without Serious Adverse Events: 6-Month Follow-up. Diabetes Care. 2021 Mar. 44 (3):844-6. [QxMD MEDLINE Link]. [Full Text].
Lewis DM. Do-It-Yourself Artificial Pancreas System and the OpenAPS Movement. Endocrinol Metab Clin North Am. 2020 Mar. 49 (1):203-13. [QxMD MEDLINE Link].
Tauschmann M, Thabit H, Bally L, et al. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. Lancet. 2018 Oct 13. 392 (10155):1321-9. [QxMD MEDLINE Link]. [Full Text].
Lilly and Ypsomed collaborate to advance an automated insulin delivery system for people with diabetes. Lilly Investors. Available at https://investor.lilly.com/news-releases/news-release-details/lilly-and-ypsomed-collaborate-advance-automated-insulin-delivery. November 19, 2020; Accessed: July 11, 2022.
Younk LM, Mikeladze M, Tate D, Davis SN. Exercise-related hypoglycemia in diabetes mellitus. Expert Rev Endocrinol Metab. 2011 Jan 1. 6 (1):93-108. [QxMD MEDLINE Link]. [Full Text].
Chung ST, Haymond MW. Minimizing morbidity of hypoglycemia in diabetes: a review of mini-dose glucagon. J Diabetes Sci Technol. 2015 Jan. 9 (1):44-51. [QxMD MEDLINE Link]. [Full Text].
Basu R, Johnson ML, Kudva YC, Basu A. Exercise, hypoglycemia, and type 1 diabetes. Diabetes Technol Ther. 2014 Jun. 16 (6):331-7. [QxMD MEDLINE Link]. [Full Text].
Klonoff DC, Kerr D. Smart Pens Will Improve Insulin Therapy. J Diabetes Sci Technol. 2018 May. 12 (3):551-3. [QxMD MEDLINE Link]. [Full Text].
Galindo RJ, Ramos C, Cardona S, et al. Efficacy of a Smart Insulin Pen Cap for the Management of Patients with Uncontrolled Type 2 Diabetes: A Randomized Cross-Over Trial. J Diabetes Sci Technol. 2021 Jul 22. 19322968211033837. [QxMD MEDLINE Link]. [Full Text].
Companion Medical InPen Receives FDA Clearance for Expanded Pediatric Use. Cision PR Newswire. Available at https://www.prnewswire.com/news-releases/companion-medical-inpen-receives-fda-clearance-for-expanded-pediatric-use-301081939.html. June 23, 2020; Accessed: July 11, 2022.
Sangave NA, Aungst TD, Patel DK. Smart Connected Insulin Pens, Caps, and Attachments: A Review of the Future of Diabetes Technology. Diabetes Spectr. 2019 Nov. 32 (4):378-84. [QxMD MEDLINE Link]. [Full Text].
Rodbard D, Garg SK. Standardizing Reporting of Glucose and Insulin Data for Patients on Multiple Daily Injections Using Connected Insulin Pens and Continuous Glucose Monitoring. Diabetes Technol Ther. 2021 Mar. 23 (3):221-6. [QxMD MEDLINE Link]. [Full Text].
Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013 Mar. 15 (3):198-211. [QxMD MEDLINE Link].
Shah VN, Garg SK. Standardized Hybrid Closed-Loop System Reporting. Diabetes Technol Ther. 2021 May. 23 (5):323-31. [QxMD MEDLINE Link]. [Full Text].
Al-Badri M, Hamdy O. Diabetes clinic reinvented: will technology change the future of diabetes care?. Ther Adv Endocrinol Metab. 2021. 12:2042018821995368. [QxMD MEDLINE Link]. [Full Text].
de Kreutzenberg SV. Telemedicine for the Clinical Management of Diabetes; Implications and Considerations After COVID-19 Experience. High Blood Press Cardiovasc Prev. 2022 Jul. 29 (4):319-26. [QxMD MEDLINE Link]. [Full Text].
Chamberlain JJ. Continuous Glucose Monitoring Systems: Categories and Features. Role of Continuous Glucose Monitoring in Diabetes Treatment. 2018 Aug. [QxMD MEDLINE Link]. [Full Text].